Physician profile
James R Varrell
NPI 1689779043
$799.64
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.54 · 2020: $299 · 2021: $357 · 2022: $72.44 · 2023: $27.88 · 2024: $14.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $180.26 | 2020-2021 | |
| Brainsway USA INC | $141.35 | 2020 | |
| Abbvie INC. | $130.31 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $83.74 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $71.14 | 2019-2023 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $42.40 | 2020-2021 | |
| Alkermes, INC. | $40.76 | 2020-2021 | |
| Bausch Health US, LLC | $28.46 | 2020-2021 | |
| Neos Therapeutics, LP | $27.09 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $14.59 | 2024 | |
| Eisai INC. | $13.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.50 | 2023 | Spravato |
| Vanda Pharmaceuticals INC. | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Varrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.